FRAZER, Pa., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced Frank Baldino, Jr., Ph.D., the company's Chairman and Chief Executive Officer, will not be resuming his duties at the company in 2010. He will remain on a medical leave of absence indefinitely. During Dr. Baldino's leave, J. Kevin Buchi, the company's Chief Operating Officer, will continue to perform Dr. Baldino's day-to-day responsibilities pending his return.
William P. Egan, Cephalon's Presiding Director, said, "In Frank's absence, Kevin continues to have the complete confidence and full support of the Board."
About Cephalon, Inc.Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.
More information on Cephalon and its products is available at http://www.cephalon.com
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products,
|SOURCE Cephalon, Inc.|
Copyright©2010 PR Newswire.
All rights reserved